Gallium-68 PSMA

Drug Profile

Gallium-68 PSMA

Alternative Names: (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; (68Ga)PSMA-HBED-CC; 68Ga-DKFZ-PSMA-11; 68Ga-HBED-CC-PSMA; 68Ga-HBED-PSMA; 68Ga-PSMA; 68Ga-PSMA HBED-CC; 68Ga-PSMA HBED-PET/CT; 68Ga-PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-PSMA-11; 68Ga-PSMA-ligand; Ga-68 labeled DKFZ-PSMA-11; Ga-68 labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; Ga-68 labeled Glu-urea-Lys(Ahx)-HBED-CC; Ga-68 labeled PSMA-11 PET; Ga-68-PSMA-11; Gallium-68 labeled PSMA-11; ProstaMedix; PSMA-HBED-CC GA-68

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RadioMedix
  • Developer Chang Gung Memorial Hospital; Friedrich-Alexander-University Erlangen-Nuremberg; German Cancer Research Center; Institut de Cancerologie de l'Ouest; Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori; Jewish General Hospital; Medical University of Vienna; Princess Alexandra Hospital; Sir Charles Gairdner Hospital; University Medical Center Groningen; University of California at San Francisco; University of Zurich
  • Class Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Adenocarcinoma; Renal cell carcinoma; Thyroid cancer
  • Clinical Phase Unknown Solid tumours

Most Recent Events

  • 14 Mar 2018 Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori plans the BIOPSTAGE trial for Prostate cancer (Diagnosis) in Italy in April 2017 , (NCT03465579)
  • 16 Feb 2018 University of Iowa initiates enrolment in a phase II/III trial for Prostate Cancer (Diagnosis) in USA (IV) (NCT03389451)
  • 12 Feb 2018 Indiana University plans a phase II trial for Prostate Cancer (Diagnosis) in USA , (NCT03429244)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top